Senate Republicans go weak on spending cuts

Exploring recent financial news, Zeekr sees a significant rise in sales, dominating the Russian electric vehicle market. Elsewhere, insights on the value of investing in stocks with low price-to-book ratios are shared, alongside a list of 14 undervalued stocks. In contrast, a strategist predicts a substantial downturn in the stock market, projecting a 30% fall due to an impending U.S recession.

Why did President Trump’s tariff announcements send Nike stock spinning? And what’s weighing on the Magnificent Seven tech stocks? Plus, how did shares of conservative news outlet Newsmax do in their first trading week? Host Krystal Hur discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Cathie Wood invests in CrowdStrike during a market dip, while a market strategist highlights Tesla as primarily a story about Elon Musk and technology, rather than just electric vehicles. Meanwhile, a significant stock market rotation is reportedly developing, marking a potentially historic shift in investment trends.

hVIVO PLC chief executive Yamin ‘Mo’ Khan takes Proactive's Stephen Gunnion through the company’s record-breaking financial performance in 2024, operational milestones and strategic outlook. hVIVO reported a 12% rise in revenue to just under £63 million, with an EBITDA margin of 26%. Khan highlighted this as a record margin for the company. He noted that, even excluding a one-off facility fee, the margin remained strong at 23%. The company also ended the year with £44 million in cash. Khan explained: “This is all been based on a record number of inoculations… we ran nine challenge trials and our largest field study to date.” He emphasised the company’s transformation, with a move to a purpose-built 50-bed human challenge facility in Canary Wharf, improvements in operational efficiency, and a major expansion of lab and outpatient capacity. Looking ahead, hVIVO is targeting £73 million in revenue for 2025, of which £70 million is already contracted. The company is also launching new challenge models, including Omicron and hMPV, and pursuing its first phase 3 human trial. Khan also discussed recent acquisitions—CRS in Germany and Cryostore in the UK—and confirmed continued dividend payments, with 0.2p per share set for June. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates. #hVIVO #ClinicalTrials #HumanChallengeTrials #BiotechNews #EBITDA #RevenueGrowth #Biopharma #DrugDevelopment #CRSAcquisition #CryoStore #VaccineTrials #AntiviralResearch #LifeSciences #PharmaPipeline